Tyra Biosciences (TYRA) Cash & Equivalents (2020 - 2026)

Tyra Biosciences' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $85.0 million for Q1 2026.

• Quarterly Cash & Equivalents fell 15.65% year-over-year to $85.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $85.0 million (down 15.65% YoY) and the FY2025 annual result came in at $77.4 million, down 15.85% from the prior year.
• Cash & Equivalents was $85.0 million for Q1 2026 at Tyra Biosciences, up from $77.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $292.5 million in Q1 2022 and bottomed at $58.0 million in Q4 2023.
• A 5-year average of $164.9 million and a median of $103.9 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents soared 107.98% — and 2023, when it tumbled 76.91%.
• Tyra Biosciences' Cash & Equivalents stood at $251.2 million in 2022, then tumbled by 76.91% to $58.0 million in 2023, then surged by 58.55% to $92.0 million in 2024, then dropped by 15.85% to $77.4 million in 2025, then gained by 9.78% to $85.0 million in 2026.
• Business Quant data shows TYRA's Cash & Equivalents at $85.0 million in Q1 2026, $77.4 million in Q4 2025, and $62.0 million in Q3 2025.